University of Pittsburgh Secures $1m NIH Grant for Collaboration with Tiba Biotech Developing RNA-based COVID-19 Vaccine

Founded in 2016, this pre-clinical stage biotechnology company seeks to revolutionize the design and delivery of a safer, more effective and affordable generation of nucleic acid products for human and animal health. The company positions that its RNA vaccine platform disrupts existing design, delivery and bio-manufacturing processes while enabling the rapid development of highly effective vaccines against multiple diseases. Read more ->